AI Article Synopsis
- - Bladder cancer (BC) is the most prevalent type of cancer in the urothelial tract, presenting significant challenges due to its high rates of incidence, recurrence, and mortality.
- - Despite some benefits from immunotherapies, BC remains predominantly incurable, especially in advanced stages, with epigenetic changes like DNA methylation and non-coding RNA alterations playing a critical role in its development.
- - Recent research highlights the potential of these epigenetic changes as biomarkers and therapeutic targets, offering hope for improved management strategies for bladder cancer in the future.
Article Abstract
Bladder cancer (BC) is the most common neoplasia of the urothelial tract. Due to its high incidence, prevalence, recurrence and mortality, it remains an unsolved clinical and social problem. The treatment of BC is challenging and, although immunotherapies have revealed potential benefit in a percentage of patients, it remains mostly an incurable disease at its advanced state. Epigenetic alterations, including aberrant DNA methylation, altered chromatin remodeling and deregulated expression of non-coding RNAs are common events in BC and can be driver events in BC pathogenesis. Accordingly, these epigenetic alterations are now being used as potential biomarkers for these disorders and are being envisioned as potential therapeutic targets for the future management of BC. In this review, we summarize the recent findings in these emerging and exciting new aspects paving the way for future clinical treatment of this disease.
Download full-text PDF |
Source |
|---|---|
| http://www.ncbi.nlm.nih.gov/pmc/articles/PMC6902278 | PMC |
| http://dx.doi.org/10.3389/fgene.2019.01125 | DOI Listing |
Publication Analysis
Top Keywords
Similar Publications
Want AI Summaries of new PubMed Abstracts delivered to your In-box?
Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!